Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : Canadian Institute of Health Resources
Deal Size : $1.1 million
Deal Type : Funding
Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease
Details : The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD. Arch Biopartners is developing a pipeline of new candidates that inhibit inflammation in the lungs, liver, and kidneys via D...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
February 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : Canadian Institute of Health Resources
Deal Size : $1.1 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : University of Michigan
Deal Size : Undisclosed
Deal Type : Collaboration
Walden Biosciences Announces Research Collaboration with University of Michigan
Details : U-M will collaborate with Walden Biosciences in connection with Dr. Hayek’s ongoing research in the area of suPAR and Walden will provide materials, data analysis, and may perform experiments to support the work, including the role of polymorphisms in ...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : University of Michigan
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AI-generated target was identified through Benevolent Platform® and AstraZeneca's scientific expertise and rich datasets. The Benevolent Platform® predicted this novel target, which was subsequently biologically validated through AstraZeneca's rigorous...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SFX-01
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : Evgen Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Evgen and Rochester University partner to advance SFX-01 trial
Details : Under the agreement, Evgen will supply SFX-01 to support a potential future clinical trial led by University of Rochester Nephrology division chief Thu Le.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 18, 2020
Lead Product(s) : SFX-01
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : Evgen Pharma
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?